Liberum Capital reiterated their hold rating on shares of Shire (LON:SHP) in a report issued on Wednesday morning. The brokerage currently has a GBX 4,000 ($55.26) target price on the biopharmaceutical company’s stock.
SHP has been the subject of a number of other reports. JPMorgan Chase & Co. cut Shire to a neutral rating and cut their price objective for the company from GBX 5,000 ($69.08) to GBX 3,600 ($49.74) in a research report on Tuesday, February 20th. Shore Capital reaffirmed a buy rating on shares of Shire in a research report on Monday, November 13th. HSBC cut their price objective on Shire from GBX 4,050 ($55.95) to GBX 3,800 ($52.50) and set a hold rating for the company in a research report on Tuesday, November 21st. Deutsche Bank reaffirmed a buy rating on shares of Shire in a research report on Monday, December 11th. Finally, Citigroup reaffirmed a buy rating and issued a GBX 5,500 ($75.99) price objective on shares of Shire in a research report on Friday, January 5th. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Shire presently has an average rating of Buy and an average target price of GBX 4,955.88 ($68.47).
Shire (LON:SHP) opened at GBX 3,192.50 ($44.11) on Wednesday. Shire has a 52-week low of GBX 2,940.50 ($40.63) and a 52-week high of GBX 5,021 ($69.37). The company has a market capitalization of $29,260.00 and a P/E ratio of 2,186.64.
In other news, insider Dominic Blakemore purchased 165 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was acquired at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).
COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2018/03/10/liberum-capital-reiterates-hold-rating-for-shire-shp.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.